Aurinia Pharmaceuticals Inc. (FRA:IKAP)
Germany · Delayed Price · Currency is EUR 13.88
-0.20 (-1.42%)
Last updated: Nov 27, 2025, 8:02 AM CET
Aurinia Pharmaceuticals Company Description
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 130 |
| CEO | Peter Greenleaf |
Contact Details
Address: #140, 14315 – 118 Avenue Edmonton, Alberta T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | IKAP |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Greenleaf | Chief Executive Officer |
| Joseph Miller | Chief Financial Officer |
| Matthew Donley | Chief Operating Officer |
| Andrea Christopher | Head of Investor Relations |